The Future of Sickle Cell Disease

Sickle cell disease is a chronic, inherited blood disorder in which the red blood cells are shaped like crescents, which causes restricted blood flow. Sickle cell is characterized by frequent hospitalization, damage to vital organs, and chronic pain. The disease disproportionately affects those of African, Caribbean, South Asian, and Middle Eastern descent. It affects approximately 100,000 people in the United States. As a result of the disease producing damaged blood cells in the brain, it can trigger a stroke, and in the chest, it can cause a pneumonia-like condition, making it life-threatening. A person with sickle cell disease can take medication to help their red blood cells stay rounder, but the effectiveness of this is very limited. 

Sickle Cell disease causes a variety of symptoms, one of them being anemia, which is a shortage of red blood cells, causing fatigue in patients. Sickle cells also cause episodes of pain, which can vary in intensity and can last for a few hours or up to multiple days. Patients may also experience swelling of the hands and feet, as well as infections.  Sickle Cell also may cause vision problems because of the tiny blood vessels that supply blood to the eyes becoming clogged with sickle cells. This disease may also cause a delay in puberty as a shortage of healthy red blood cells that provide oxygen/nutrients inhibits growth.

In the past, the only cure has been through a bone marrow transplant from a sibling donor, but an amazing scientific breakthrough through gene therapy has changed that. In the past 10 years, more and more people have been cured of sickle cell disease. 

Sebastian  Baeuzile, 1 21 years old, became the first patient from New York state to be cured of sickle cell anemia through gene therapy treatment. Using lovitibeglogene autotemcel uses a patient's blood stem cells and genetically modifies them to produce HBA, which functions as hemoglobin. HBA contains red blood cells that are significantly less likely to obstruct blood flow because they are less likely to sickle. Once the patient's blood cells are collected, chemotherapy is used to remove cells from the bone marrow and to replace them with modified ones. These new cells are then used as a stem cell transplant. For patients using this therapy, it was successful with a resolution of symptoms for 88% of patients within 6 to 18 months. However, Lovitibeglogne Autometcel is not accessible, as it is priced at approximately 3.1 million per treatment. Proving that despite medical innovations being made,  not everyone has the ability to truly access them.

Casgevy is another cell-based gene therapy

that has been approved for the treatment of sickle cell disease. Casgevy specifically utilizes CRISPR/ CAS9 as a genome editing technology. It cuts DNA in targeted areas with the ability to edit DNA where it is cut. The modified blood stem cells are then transplanted back into the patient, and this helps increase the production of hemoglobin. Lyfgenia is another type of cell-based gene therapy that uses lentiviral vectors for genetic modification. Lyfgenia genetically modifies the patient's blood stem cells.

These treatments that have been approved are an important medical advancement within the use of cell-based gene therapies, which are not only improving public health but also the future of those dealing with sickle cell disease.

Works Cited

Food and Drug Administration. “FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease.” FDA, 8 Dec. 2023, www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease.

Gerlach, Alexandra. “Patient Cured of Sickle Cell Anemia with Innovative Gene Therapy.” Pharmacy Times, 17 Mar. 2025, www.pharmacytimes.com/view/patient-cured-of-sickle-cell-anemia-with-innovative-gene-therapy.

Mayo Clinic. “Sickle Cell Anemia.” Mayo Clinic, 17 May 2025, www.mayoclinic.org/diseases-conditions/sickle-cell-anemia/symptoms-causes/syc-20355876.

“No More Pain: Breakthrough Sickle Cell Treatment from Johns Hopkins Offers Curative Potential.” Hopkinsmedicine.org, 2025, www.hopkinsmedicine.org/news/newsroom/news-releases/2025/06/no-more-pain-breakthrough-sickle-cell-treatment-from-johns-hopkins-offers-curative-potential.

Philadelphia, The Children’s Hospital of. “Gene Therapy for Sickle Cell Disease: Marie-Chantal’s Story.” Www.chop.edu, 22 Nov. 2023, www.chop.edu/stories/gene-therapy-sickle-cell-disease-marie-chantal-s-story.

Assessed and Endorsed by the MedReport Medical Review Board